Back to Search
Start Over
Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
- Source :
-
International journal of obesity (2005) [Int J Obes (Lond)] 2022 Nov; Vol. 46 (11), pp. 2058-2062. Date of Electronic Publication: 2022 Aug 18. - Publication Year :
- 2022
-
Abstract
- We investigated the effect of pharmacologically induced weight loss on markers of glucagon resistance in individuals with overweight during treatment with the glucagon-like peptide-1 receptor agonist liraglutide. We performed an open-label study in 14 men with overweight (age 38 ± 11 years, BMI 32 ± 4 kg/m <superscript>2</superscript> ) without simultaneously diabetes. Subjects were treated with liraglutide, initiated and titrated with 0.6 mg/day/week to reach the final dose of 3.0 mg/day. Subjects were examined at baseline, during titration (Week 4), after 2 weeks of steady state (Week 6) of final dosing of liraglutide and 3 weeks after discontinuation of liraglutide (follow-up). Study participants lost 3.3 ± 1.9 kg (3%) total body weight during the first 4 weeks of treatment with liraglutide. Simultaneously, liver fat content decreased from 12.4 ± 11.6% to 10.2 ± 11.1%, p = 0.025, whereas fat content in the spleen and subcutaneous tissue was unaltered. Markers of glucagon resistance, including plasma glucagon and the glucagon-alanine-index, also decreased significantly during treatment, but total and individual plasma amino acid concentrations did not. Insulin resistance (HOMA-IR) was unchanged during treatment, whereas insulin clearance increased. Treatment with the GLP-1 receptor analogue liraglutide decreased liver fat content, and simultaneously attenuated glucagon concentrations and the glucagon-alanine index in individuals with overweight without diabetes.<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
- Subjects :
- Humans
Male
Adult
Middle Aged
Glucagon-Like Peptide-1 Receptor agonists
Glucagon
Overweight drug therapy
Overweight metabolism
Hypoglycemic Agents pharmacology
Hypoglycemic Agents therapeutic use
Insulin therapeutic use
Liver metabolism
Alanine therapeutic use
Amino Acids
Liraglutide pharmacology
Liraglutide therapeutic use
Diabetes Mellitus, Type 2 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5497
- Volume :
- 46
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- International journal of obesity (2005)
- Publication Type :
- Academic Journal
- Accession number :
- 35982119
- Full Text :
- https://doi.org/10.1038/s41366-022-01207-y